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Abstract 
 
Constitutive activation of the transcription factor STAT3 contributes to the pathogenesis 
of many cancers, including multiple myeloma (MM).  Since STAT3 is dispensable in most 
normal tissue, targeted inhibition of STAT3 is an attractive therapy for patients with these 
cancers.  To identify STAT3 inhibitors, we developed a transcriptionally based assay and 
screened a library of compounds known to be safe in humans.  We found the drug nifuroxazide 
to be an effective inhibitor of STAT3 function.  Nifuroxazide inhibits the constitutive 
phosphorylation of STAT3 in MM cells by reducing Jak kinase autophosphorylation, and leads 
to downregulation of the STAT3 target gene Mcl-1.  Nifuroxazide causes a decrease in viability 
of primary myeloma cells and myeloma cell lines containing STAT3 activation, but not normal 
peripheral blood mononuclear cells.  Although bone marrow stromal cells provide survival 
signals to myeloma cells, nifuroxazide can overcome this survival advantage.  Reflecting the 
interaction of STAT3 with other cellular pathways, nifuroxazide shows enhanced cytotoxicity 
when combined with either the histone deacetylase inhibitor depsipeptide or the MEK inhibitor 
UO126.  Therefore, using a mechanistic-based screen, we identified the clinically relevant drug 
nifuroxazide as a potent inhibitor of STAT signaling which shows cytotoxicity against myeloma 
cells that depend on STAT3 for survival.
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Introduction 
 
Signal transducers and activators of transcription (STATs) are a family of transcription 
factors essential for the pathogenesis of many cancers 
1.  In normal cells, signaling initiated by 
cytokines and growth factors leads to the transient activation of STATs by tyrosine kinases, such 
as members of the Janus kinase (Jak) family.  Activation involves phosphorylation of a tyrosine 
residue near the carboxyl terminus followed by dimerization of two STAT monomers.  These 
activated STATs enter the nucleus, and regulate gene transcription by binding to specific DNA 
regulatory elements.  STATs have long been known for their ability to upregulate genes; 
however, emerging evidence demonstrates that STATs can also downregulate key target genes 
2,3.  Soon after activation, STATs are typically dephosphorylated, ending the signaling process.  
In cancer, STAT activation is often constitutive 
4.  This can occur through a variety of 
mechanisms, such as positive signaling from mutated kinases, or by a lack of negative regulation 
by phosphatases or other feedback inhibitors.  This continuously activated state leads to the 
inappropriate regulation of genes that are important for survival and proliferation, and that are 
known to contribute to the malignant phenotype. 
STAT3 in particular has been found to be a critical mediator in the pathogenesis of many 
tumors.  STAT3 is activated by a number of factors including IL-6, a cytokine essential for the 
survival of many cell lineages, including B lymphocytes and plasma cells.  Multiple myeloma 
(MM) is a plasma cell malignancy often characterized by the constitutive activation of STAT3 
5.  
In the bone marrow environment, cytokines such as IL-6 can be secreted by stromal cells or the 
myeloma cells themselves, and the presence of these cytokines can promote the continued 
survival and proliferation of MM cells 
6.  Thus, the pathogenesis of MM depends on STAT3 
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signaling, and interruption of this signaling pathway may lead to the death of these cancer cells. 
To develop targeted inhibitors of STAT3 function for the treatment of MM and other 
forms of cancer, we developed a cell-based assay to measure STAT3-dependent transcriptional 
activity.  To accelerate the identification of agents that could be used in clinical trials, we utilized 
this system to perform a high throughput screen of compounds known to be bioactive, including 
many drugs presently in clinical use for a variety of diseases. 
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Materials and Methods 
       
Cell culture:  RPMI 8266, H929, and U266 myeloma cells were obtained from ATCC 
(Manassas, VA) and were grown in RPMI media containing 10% fetal calf serum.  293 human 
embryonic kidney cells (ATCC) were grown in DMEM containing 10% fetal calf serum.  The 
IL-6 dependent INA6 myeloma cell line 
7 was obtained from Dr. Renate Burger (University of 
Kiel, Kiel, Germany), and was grown in RPMI media containing 10% fetal calf serum 
supplemented with 1 ng/ml IL-6 (Peprotech, Rocky Hill, NJ).  STAT1-null U3A cells and the 
parental 2FTGH cells were a gift from Dr. George Stark (Cleveland Clinic, Cleveland, OH), and 
were grown in DMEM containing 10% fetal calf serum.  T47D human mammary carcinoma 
cells (ATCC) were grown in DMEM containing 10% fetal calf serum.  Bone marrow 
mononuclear cells from patients with untreated multiple myeloma were obtained through a 
Dana-Farber Cancer Institute IRB-approved protocol, and were cultured in RPMI media 
containing 10% fetal calf serum. 
 
Antibodies:  Antibodies recognizing STAT3 (sc-482), Jak2 (sc-278), Jak1 (sc-295), Tyk2 (sc-
169), c-src (sc-18), and Mcl-1 (sc-819) were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA); tyrosine-phosphorylated STAT3 (9131L), and pan-phospho-tyrosine (9411 and 9416) 
were from Cell Signaling Technology; epidermal growth factor receptor (EGFr) (2232), Parp 
(9542), p-STAT3 (9131L), and pan-phospho-tyrosine (9411 and 9416), p-src (2101), p-EGFr 
(2234), and p-Jak1 (3331) were from Cell Signaling Technology; anti-tyrosine 4G10 platinum 
(05-1050x) was from Millipore; tubulin was from Sigma (St. Louis, MO); and serine 
phosphorylated STAT3 was generated as described 
8. 
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Compounds:  The Prestwick chemical library was obtained from Prestwick Chemical Company 
(Illkirch, France).  Nifuroxazide (cat. number 5227235) was obtained from Chembridge (San 
Diego, CA), and was dissolved in DMSO at a concentration of 150 mM.  Jak inhibitor 1 
(420099) , WP1066 (573097), and AG490 (658401) were obtained from EMD (La Jolla, CA).  
The final concentration of DMSO in cellular experiments was 0.1%. 
 
Generation of reporter cell lines: To measure STAT3-dependent luciferase activity, the STAT-
luc/U3A cell line was utilized 
9.  A STAT1-responsive line (STAT-luc/2FTGH) was generated 
by co-transfecting pIRES-puro with a STAT-responsive luciferase plasmid 
10 into 2FTGH cells.  
A STAT5-responsive line (NCAM2-luc/T47D) was generated by co-transfecting pIRES-puro 
with a STAT5-responsive NCAM2-luciferase construct 
11 into T47D cells.  An NF-κB-
responsive cell line (NF-κB-luc/293) was generated by co-transfecting pIRES puro with an NF-
κB responsive reporter plasmid (cat. number 219078, Stratagene, La Jolla, CA) into 293 cells.  
After selection, individual clones were isolated.  To assess reporter gene activity, STAT-luc/U3A 
cells were stimulated for 6 hours with 10 ng/ml IL-6; STAT-luc/2FTGH cells were stimulated 
with 500 units/ml IFNγ; NCAM2-luc/T47D cells were stimulated with 100ng/ml prolactin; NF-
κB-luc/293 cells were stimulated for six hours with 10 ng/ml TNFα.  IL-6 and TNFα were 
obtained from Peprotech (Rocky Hill, NJ), while IFNγ and prolactin were obtained from R&D 
Systems (Minneapolis, MN). 
 
Identification of STAT3 inhibitors:  To identify STAT3 inhibitors, we screened the Prestwick 
Chemical Library, which contains 1120 bioactive compounds.  Compounds were tested for their 
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ability to modulate STAT3 activity utilizing the STAT-luc/U3A cells.  To eliminate compounds 
displaying non-specific activity, a counter screen was performed using the NF-κB-luc/293 cells. 
2.5 X 10
3 cells were plated in triplicate in 30 μl media in an opaque 384 well dish.  The 
following day, 100 nl (2 mg/ml) of each compound from the library were transferred to the cells.  
After one hour of incubation, cytokines were added at the indicated concentrations.  For 
confirmation of inhibitory activity, and for testing compounds for STAT1 and STAT5 inhibitory 
activity, 1 X 10
4 cells were plated in opaque 96 well plates.  The following day, drug was added 
for one hour, after which cytokines were added.  Six hours later, luciferase activity was 
quantitated using the Bright-Glo Luciferase Assay System from Promega (Madison, WI) and a 
Luminoskan Ascent luminometer from Labsystems (Helsinki, Finland). 
 
Western blotting and immunoprecipitation: Protein was isolated from myeloma cells by 
incubating cells on ice for 15 minutes in lysis buffer (50 mM Tris, pH 8.0, 250 mM NaCl, and 
0.5% NP40) supplemented with sodium vanadate and Complete Protease Inhibitors (Roche, 
Indianapolis, IN).  Lysates were cleared by centrifugation.  Protein concentration was quantitated 
using the Bradford Reagent (Bio-Rad Laboratories, Hercules, CA).  Lysates were mixed with 2X 
sample buffer (0.125 M Tris, pH 6.8, 4% SDS, 20% glycerol) containing 4% β-mercaptoethanol 
and boiled for 5 minutes.  For STAT analysis, protein was resolved on an 8% acrylamide gel, 
and for Mcl-1 analysis, protein was resolved on a 12% gel, then transferred to nitrocellulose.  
Membranes were blocked in 5% milk in TBST (USB, Cleveland, Ohio) for 1 hour.  Blots were 
washed in TBST and incubated with the appropriate horseradish peroxidase-labeled secondary 
antibody.  Following washing in TBST, the blots were developed using Western Blot 
Chemiluminescence Reagent Plus (PerkinElmer, Boston, MA).  For immunoprecipitations, cells 
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were lysed on ice for 15 minutes in RIPA buffer (150 mM NaCl, 50 mM Tris, pH 7.4, 1% NP40, 
0.5% sodium deoxycholate, and 0.1% SDS) supplemented with sodium vanadate and protease 
inhibitors.  Lysates were cleared by centrifugation.  The supernatant was incubated with the 
indicated antibody overnight.  Protein A/G Plus beads (Santa Cruz Biotechnology, Santa Cruz, 
CA) were added and incubated for 2 hours, after which the beads were washed 4 times in RIPA 
buffer.  The beads were resuspended in 2X sample buffer containing 10% β-Mercaptoethanol 
and boiled for 5 minutes.  Quantitation of band intensity was performed using ImageJ software 
(http://rsb.info.nih.gov/ij/index.html). 
 
Viability assays: 1 X 10
4 cells were plated in opaque 96 well dishes.  Compound or vehicle was 
added to yield a total volume of 100 μl.  At the indicated times, cell viability was assessed using 
the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). 
 
Bone marrow stromal cell (BMSC) culture:  Following IRB approval from the Dana-Farber 
Cancer Institute and informed consent in accordance with the Declaration of Helsinki, bone 
marrow specimens were obtained from patients with MM.  Mononuclear cells (MNCs) separated 
by Ficoll-Hipaque density sedimentation were used to establish long-term BMSC cultures, as 
previously described 
12, except no growth factors were added.  When an adherent cell monolayer 
developed, cells were harvested in Hank’s Buffered Saline Solution containing 0.25% trypsin 
and 0.02% EDTA, washed, and collected by centrifugation.  For co-culture experiments, 5 X 10
5 
BMSCs were seeded into a 25 cm
2 flask and cultured overnight.  The cells were washed three 
times with PBS, and U266 cells were added.  The co-culture was maintained for 48 hours after 
drug addition, after which, the U266 cells were collected for protein isolation. 
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Gene expression analysis.  Cells were incubated for the indicated times with either compound 
or vehicle, and RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA).  cDNA was 
generated using the Taqman reverse transcription kit (Applied Biosystems, Foster City, CA). 
Quantitative real time PCR was performed in triplicate using SYBR green master mix (Applied 
Biosystems) on a model 7500 real time PCR system (Applied Biosystems).  Data are expressed 
as the mean-fold change + S.E. of three replicates. Each assay was repeated at least three times.  
Primers used were:  Mcl-1,
 forward, GAGACCTTACGACGGGTT and reverse, 
TTTGATGTCCAGTTTCCG; HPRT, forward, GAACGTCTTGCTCGAGATGTG and reverse, 
CCAGCAGGTCAGCAAAGAATT. 
 
Statistical analysis.  Analysis of the effects of combinations of agents was performed using 
CalcuSyn software (Conservion, Ferguson, MO) using previously established parameters for 
determining synergy 
13.
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Results 
 
Identification of nifuroxazide as a STAT inhibitor.  To assess the ability of compounds to 
inhibit STAT3 function, we utilized U3A cells stably expressing a luciferase reporter gene under 
the control of a STAT-dependent promoter 
9.  Basal luciferase expression is minimal in these 
cells.  However, when they are treated with IL-6, robust and reproducible luciferase expression 
can be detected. While STAT1 can also activate this promoter, U3A cells lack STAT1, and thus 
luciferase activity in these cells is completely dependent upon STAT3 function.  We employed 
this cell line to interrogate the Prestwick Library of 1120 bioactive compounds to identify 
clinically relevant drugs that specifically inhibit STAT3 function.  To eliminate compounds that 
broadly inhibit gene expression, we performed a parallel counter screen using the NF-κB-luc/293 
cell line in which luciferase expression is driven by the transcription factor NF-κB.  Through this 
approach, we identified nifuroxazide as a potent inhibitor of STAT3 (Figure 1a).  Nifuroxazide 
inhibited STAT3 dependent luciferase activity, with an EC50 of approximately 3 μM (Figure 1b).   
By contrast, at concentrations up to 10 μM nifuroxazide had essentially no effect on NF-κB-
dependent luciferase expression.  Thus, nifuroxazide is a potent inhibitor of STAT3 function. 
 
Nifuroxazide inhibits STAT3 tyrosine phosphorylation.  Having shown that nifuroxazide 
inhibits STAT3 function, we next examined the mechanism for this effect.  Since tyrosine 
phosphorylation is a critical event for STAT3 activation, we analyzed the effect of nifuroxazide 
on the constitutive STAT3 tyrosine phosphorylation found in U266 myeloma cells.  When U266 
cells were incubated with nifuroxazide, a significant dose-dependent decrease in STAT3 tyrosine 
phosphorylation was observed, reaching approximately 50% inhibition at a concentration of 10 
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μM (Figure 2a).  This was comparable to the inhibition of STAT3-dependent reporter gene 
activity seen with this drug (Figure 1b).  This inhibition of STAT3 tyrosine phosphorylation was 
rapid, occurring as early as one hour after treatment, and was sustained for at least 24 hours 
(Figure 2b).  STAT3 can also be phosphorylated on a carboxy-terminal serine residue, serine 
727, and this modification may modulate STAT3 transcriptional activity.  U266 cells contain 
STAT3 that is constitutively phosphorylated on serine 727, but this modification is unaffected by 
nifuroxazide treatment (Figure 2b).  Thus, nifuroxazide inhibits STAT3 activity through the 
inhibition of STAT3 tyrosine phosphorylation. 
 
Nifuroxazide inhibits Jak kinase phosphorylation.   Given these findings, we next determined 
if an upstream tyrosine kinase is affected by nifuroxazide treatment.  IL-6 autocrine and 
paracrine loops play a role in the pathogenesis of many cases of MM 
14, and thus we focused on 
the Jak family kinases, Jak2, Tyk2, and Jak1, which are the central mediators of the effects of IL-
6 
15.  To determine the effect of nifuroxazide on the activation of these kinases, we performed 
immunoprecipitations  to determine their level of tyrosine phosphorylation, which reflects their 
kinase activity.  IL-6 dependent INA6 MM cells were treated with 10 μM nifuroxazide for six 
hours, after which immunoprecipitations were performed to Jak2, Tyk2, Jak1, or STAT3. 
Western blotting was then performed using an antibody specific for phosphotyrosine to 
determine the activation state of these proteins.  As expected, nifuroxazide led to a decrease in 
tyrosine phosphorylation of STAT3 by almost 70% (Figure 2c).  In addition, the tyrosine 
phosphorylation of Jak2 and Tyk2 showed decreases of approximately 50%, while the low level 
of Jak1 phosphorylation was little changed.  This suggested that nifuroxazide decreased STAT3 
phosphorylation in these cells through an inhibition in upstream Jak kinases.  To determine 
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whether nifuroxazide inhibits tyrosine kinases broadly, we examined the effect of this drug on 
the EGF receptor tyrosine kinase (in HCC-827 cells) and Src (in A549 cells).  Neither showed a 
significant change in activity (data not shown), indicating that nifuroxazide is relatively specific 
for Jak2 and Tyk2. 
 
Having shown that nifuroxazide can inhibit Jak2 and Tyk2, we considered the possibility that 
nifuroxazide could inhibit the activation of other STAT family members which may be activated 
by these kinases.  Using luciferase reporter systems dependent on the activation of STAT1 by 
interferon-γ or the activation of STAT5 in response to prolactin, we found that nifuroxazide 
could inhibit both of these reporter systems with a similar dose response as seen for STAT3 (data 
not shown). Thus, nifuroxazide can inhibit the activation of several STAT family members in 
Jak-dependent systems.   
 
Nifuroxazide inhibits expression of the endogenous STAT3 target gene Mcl-1.  Having 
shown that nifuroxazide inhibits STAT3 phosphorylation and activation of a heterologous 
reporter gene, we next examined the effect of this drug on expression of an endogenous STAT3 
target gene.  We focused on Mcl-1, as this a key STAT3 target gene that is known to be critical 
for the aberrant survival and malignant phenotype of myeloma 
16.  24 hour treatment of U266 
cells with 10 μM nifuroxazide led to a 40% decrease in Mcl-1 mRNA expression when 
normalized to HPRT expression (Figure 3a).  To determine whether this led to a loss of 
expression of Mcl-1 protein, Western analysis was performed on U266 and INA6 cells treated 
with nifuroxazide.  The level of Mcl-1 protein was reduced at both 8 hours and 24 hours in both 
cell types (Figure 3b).  Thus, nifuroxazide can decrease expression of a bona fide endogenous 
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STAT3 target gene. 
 
Nifuroxazide decreases viability of myeloma cells with activated STAT3.  Given the 
evidence that STAT3 plays an essential role in the pathogenesis of myeloma, we next evaluated 
the effect of nifuroxazide on the viability of MM cell lines.  We utilized U266 and INA6 
myeloma cells that contain constitutive STAT3 phosphorylation, and RPMI 8226 and H929 cells 
that lack detectable STAT3 phosphorylation 
17.  Treatment of U266 or INA6 cells with 
nifuroxazide for 48 hours resulted in a dose-dependent loss of cell viability with an EC50 of 
approximately 4.5 μM in both cell types (Figure 4a).  Notably, the MM cells lacking constitutive 
STAT3 activation showed little toxicity to nifuroxazide.  Other known Jak inhibitors, including 
pyridone 6, AG490, and WP 1066 show similar effects in reducing INA6 viability (data not 
shown).  Importantly, peripheral blood mononuclear cells from normal donors showed 
essentially no toxicity to nifuroxazide treatment.  These results suggest that nifuroxazide does 
not show non-specific toxicity, and exerts a cytotoxic effect only on myeloma cells characterized 
by constitutive STAT3 activation. 
 
It is notable that nifuroxazide causes a prominent decrease in viability of INA6 cells while 
causing only partial inhibition of STAT3 phosphorylation.  To see if this was a characteristic of 
other Jak kinase inhibitors, we performed detailed quantitative dose response analyses of both 
cellular viability and STAT3 phosphorylation in INA6 cells treated with nifuroxazide or two 
other Jak inhibitors, WP1066 and Jak inhibitor 1.  At concentrations of these drugs that caused a 
90% decrease in viability, nifuroxazide caused a 50% decrease in STAT3 phosphorylation 
(Supplemental table 1).  Similarly, WP1066 induced a 60% decrease in STAT3 phosphorylation, 
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while Jak inhibitor 1 led to a 90% decrease in STAT3 phosphorylation.  Thus, even incomplete 
inhibition of STAT3 phosphorylation can be associated with inhibition of expression of key 
target genes (Figure 3) and substantial decreases in cellular viability. 
 
Nifuroxazide leads to a loss of viability of primary myeloma cells.  Although nifuroxazide 
shows considerable efficacy in decreasing the viability of multiple myeloma cell lines 
characterized by STAT3 activation, we wished to exclude the possibility that this was a feature 
unique to myeloma cells that had been selected for their ability to grow in vitro.  We obtained 
bone marrow specimens from six untreated myeloma patients, and assessed the effect of 
nifuroxazide on the viability of these cells.  When the cells were treated with nifuroxazide for 72 
hours, the viability of all of the patient specimens decreased with a dose response comparable to 
that seen with U266 or INA6 cells (Figure 4b).  Thus, nifuroxazide is active against primary 
myeloma samples. 
 
Nifuroxazide overcomes the pro-survival effects of bone marrow stromal cells.  Myeloma 
cells in vivo depend on survival and proliferation signals from bone marrow stromal cells, and 
thus it is essential for any effective treatment to overcome this effect 
6.  To assess the effects of 
nifuroxazide on MM cells in this environment, we first analyzed the effect of BMSC co-culture 
on STAT3 activation of the myeloma cells.  Consistent with the pro-survival effects of this 
environment, co-culture of myeloma cells with BMSC led to enhanced STAT3 tyrosine 
phosphorylation in the myeloma cells (Figure 4c).  However, nifuroxazide led to a similar 
decrease in STAT3 phosphorylation in the presence or absence of BMSC.  Furthermore, as 
expected, the presence of bone marrow stromal cells also led to increased proliferation of U266 
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cells (Figure 4d).  However, as with its effect on STAT3 phosphorylation, nifuroxazide reduced 
the proliferation of myeloma cells even in the presence of stroma, with a similar dose response as 
seen in monoculture. Thus, nifuroxazide is effective at decreasing the activation of STAT3 and 
reducing the viability of myeloma cells in an environment closely resembling that seen in vivo. 
 
Consistent with the enhanced survival and proliferation seen when MM cells are cultured in the 
presence of BMSC, phosphorylation of MAP kinase and Akt are also increased in U266 cells 
under co-culture conditions (Supplemental Figure 1).  Interestingly, in contrast to the effect of 
nifuroxazide on STAT3 phosphorylation, nifuroxazide caused a further increase in both MAP 
kinase and Akt phosphorylation.  Thus, the effects of nifuroxazide in decreasing survival and 
proliferation of myeloma cells are not mediated by inhibition of these pathways, and are more 
likely to be secondary to inhibition of STAT3. 
 
The combination of nifuroxazide and the histone deacetylase inhibitor depsipeptide leads to 
enhanced toxicity of MM cells.  There is evidence that the simultaneous inhibition of two 
signaling pathways is necessary to induce apoptosis of MM cells in the presence of bone marrow 
stromal cells 
18.  Thus we considered the possibility that a STAT3 inhibitor such as nifuroxazide 
might show enhanced cytotoxicity in combination with an agent that targeted a different 
mechanism.  Neither doxorubicin nor bortezomib showed significant combinatorial effects with 
nifuroxazide (data not shown).  However, increasing evidence has suggested that histone 
deacetylase (HDAC) inhibitors may show significant therapeutic effects in hematologic 
malignancies 
19.  We focused on depsipeptide, a natural product with extremely potent effects as 
an HDAC inhibitor 
20.  When INA6 cells were treated with the combination of nifuroxazide and 
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picomolar concentrations of depsipeptide, nearly complete cytotoxicity could be induced (Figure 
5a), with evidence of synergism with 3 μM nifuroxazide and 750 nM depsipeptide, and 5 μM 
nifuroxazide with either concentration of depsipeptide (combination index <0.5 
13).  This 
combinatorial effect did not occur in H929 cells which lack activated STAT3 (data not shown).  
Nifuroxazide combined with depsipeptide in INA6 cells resulted in an enhanced reduction in 
STAT3 tyrosine phosphorylation, as well as an increase in Parp cleavage, indicating increased 
apoptosis (Figure 5b).  Thus, the combination of STAT3 inhibition and HDAC inhibition may be 
a useful strategy for clinical trials for myeloma. 
 
The combination of nifuroxazide and MEK inhibition leads to enhanced killing of MM 
cells.  The MAP kinase pathway has been linked to survival signals for cancer cells, and 
inhibition of this pathway, together with the IL-6/STAT3 signaling pathway, leads to a loss of 
viability of MM cells 
18.  This suggested that combining a MAPK inhibitor with nifuroxazide 
might enhance the cytotoxicity of nifuroxazide.  To determine if inhibition of MAPK and 
STAT3 would result in enhanced cytotoxicity, we combined the MEK inhibitor UO126 with 
nifuroxazide and examined cellular viability.  U266 cells treated with this combination showed 
enhanced cytotoxicity compared with either treatment alone (Figure 6a).  Similar results were 
seen with INA6 cells (data not shown).  H929 cells which have no activated STAT3 do not show 
this combinatorial effect (data not shown).  These results suggest that clinically relevant MAPK 
inhibitors may be useful in combination with nifuroxazide for the treatment of patients with MM.  
 
The MAPK pathway has been linked to the serine phosphorylation of STAT3, which can 
enhance its transcriptional activity 
21.  Since STAT3 shows constitutive phosphorylation of 
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serine 727 in both U266 and INA6 cells  (Figure 2 and data not shown), we considered the 
possibility that the combinatorial effect of nifuroxazide with U0126 may be due to the loss of 
both tyrosine and serine phosphorylation of STAT3.  When U266 cells are treated with U0126, a 
slight reduction in serine phosphorylation of STAT3 is seen  (Figure 6b).   Nifuroxazide alone 
has no effect on serine phosphorylation of STAT3, and nifuroxazide does not enhance the 
inhibition of STAT3 phosphorylation induced by U0126.  We next considered the possibility that 
these drugs might cooperate in inhibiting the tyrosine phosphorylation of STAT3.  Whereas 
U0126 alone shows a modest reduction in STAT3 tyrosine phosphorylation, the combination of 
nifuroxazide and UO126 leads to nearly complete inhibition of this modification (Figure 6b).  
This suggests that the enhanced cytotoxicity of nifuroxazide combined with UO126 may be due 
to increased inhibition of tyrosine phosphorylation of STAT3. 
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Discussion 
 
While STAT3 is a critical mediator of the oncogenic phenotype of many cancers, it is not 
required for the function of most normal cells 
1.  Thus, finding effective inhibitors of STAT3 
may provide useful targeted agents for cancer therapy.  While much effort has gone into the 
development of STAT3 inhibitors, it has been difficult to introduce these agents into clinical 
trials.  To circumvent this problem, we sought to identify drugs known to be safe in humans that 
might act as effective STAT3 inhibitors.  Starting with a library of known bioactive agents, we 
identified the anti-diarrheal agent nifuroxazide as a potent inhibitor of STAT3.  Nifuroxazide 
reduces STAT3 tyrosine phosphorylation, and inhibits the viability of both primary myeloma 
cells and myeloma cell lines containing constitutive STAT3 activation.  Nifuroxazide also 
showed combinatorial effects on the viability of myeloma cells when used in conjunction with 
the histone deacetylase inhibitor depsipeptide, as well as with the MEK inhibitor UO126.  Given 
that nifuroxazide showed no effect on normal hematopoietic cells, this drug may be useful in 
clinical trials for the treatment of patients with multiple myeloma. 
 
  Although not currently available for clinical use in the United States, nifuroxazide is 
available in many countries worldwide.  In randomized double-blind control trials, nifuroxazide 
has shown benefit in adults with acute diarrhea, and is extremely well tolerated 
22.  Since it is 
generally given orally, its systemic bioavailability is unclear, and little information is available 
on the parenteral administration of nifuroxazide.  However, it is chemically related to 
nitrofurantoin, which does show good oral absorption, and is used widely for the treatment of 
urinary tract infections.  In addition, a number of analogs of nifuroxazide have been synthesized 
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23,24 and one or more of these may show STAT3 inhibitory activity as well. 
 
  Nifuroxazide appears to inhibit STAT3 phosphorylation through inhibition of the  Jak 
family kinases Jak2 and Tyk2. Given that the constitutive activation of STATs in many tumors is 
due to aberrant activation of Jaks 
25,26, nifuroxazide may be useful for the treatment of these 
other tumors as well.  Nifuroxazide is not a non-specific tyrosine kinase inhibitor, as it showed 
no effects against the EGF receptor kinase or Src.  While the full spectrum of kinases inhibited 
by nifuroxazide is not yet known, increasing evidence supports the utility of multi-kinase 
inhibitors in oncology 
27.  Thus, nifuroxazide may have broader efficacy as well. 
 
  At active concentrations, nifuroxazide inhibits STAT3 tyrosine phosphorylation by 
approximately 50%, and decreases STAT3-dependent gene expression by 50%.  This is 
consistent with findings from other approaches to inhibit STAT3 that there is likely a threshold 
effect at which STAT3-dependent gene products promote malignant cellular behavior.  For 
example, partial depletion of constitutively active STAT3 leads to prominent effects on viability 
in lung cancer cells 
28.  Similarly, in prostate cancer cells, inhibition of STAT3 phosphorylation 
with low concentrations of the Jak inhibitor AG490 (25 to 50 μM) leads to partial inhibition of 
STAT3 activation, but significant effects on cellular viability 
29.  Thus, even partial inhibition of 
STAT3 is likely to confer therapeutic benefit, although these findings can also reflect effects of 
these drugs on additional targets.  In this context, it is also notable that nifuroxazide showed no 
inhibition of Akt and MAP kinase phosphorylation.  This provides  evidence that the effects of 
this drug on myeloma cell survival and proliferation are more likely mediated by its inhibition of 
STAT signaling than one of these other pathways. 
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  Since many STAT3 target genes are pro-survival genes, it is not surprising that STAT3 
inhibition may show combinatorial effects when paired with other modalities of therapy.  We 
have shown an additive effect of nifuroxazide on the viability of myeloma cells when used in 
combination with the MEK inhibitor U0126.  It has been suggested that MAP kinases can 
mediate the serine phosphorylation of STAT3 
30, and thus the combination of a MEK inhibitor 
and an inhibitor of STAT3 tyrosine phosphorylation might show synergy based on this 
mechanism.  Inhibition of MAPK showed only a slight reduction in the constitutive serine 
phosphorylation of STAT3 found in myeloma cells.  However, the combination of U0126 with 
nifuroxazide caused a pronounced decrease in STAT3 tyrosine phosphorylation.  While the 
mechanism for this is unclear, this finding shows another level of crosstalk between the STAT3 
and MAPK pathways, and suggests that the mechanism of the combinatorial effect of 
nifuroxazide and U0126 is likely through their convergent effects on STAT3 tyrosine 
phosphorylation. 
 
Nifuroxazide also shows enhanced cytotoxicity to multiple myeloma cells when 
combined with the HDAC inhibitor depsipeptide, a drug currently in clinical trials for the 
treatment of hematological malignancies.  The exact mechanism by which HDAC inhibitors 
exert their therapeutic effect is unclear, but may involve enhanced acetylation of lysine residues 
in histones, transcription factors, and other cellular proteins 
31.  This can lead to changes in gene 
expression, though depsipeptide may also cause cell death through caspase activation 
32.  Thus, it 
is possible that the decrease in pro-survival genes mediated by STAT3 inhibition may cooperate 
with caspase activation mediated by depsipeptide to enhance cell killing.  We demonstrate that 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From   21
depsipeptide and nifuroxazide show a combinatorial effect on STAT3 activation, with a greater 
reduction in STAT3 phosphorylation when compared to cells treated with either drug alone.  In 
addition, this drug combination results in enhanced apoptosis as measured by parp cleavage.  
Given the known safety characteristics of both nifuroxazide and depsipeptide, these drugs may 
be useful in clinical trials for the treatment of myeloma. 
 
In conclusion, the development of a non-biased functional screen to identify STAT3 
inhibitors in conjunction with a chemical library biased to drugs known to be safe in humans, has 
allowed the identification of nifuroxazide as an effective inhibitor of STAT3.  Nifuroxazide 
decreases the viability of multiple myeloma cells with constitutive activation of STAT3, while 
showing minimal effects on non-transformed and normal cells.  In addition, this drug shows 
enhanced effects with agents that target other cellular pathways.  Given that STAT3 activation is 
a common event in a wide range of human cancers, and this drug has been given safely to 
humans for many years, it is possible that clinical trials exploiting this approach could be 
developed in a rapid time frame. 
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From   22
Acknowledgements 
  
We wish to thank the National Cancer Institute and the Initiative for Chemical Genetics, who 
provided support for this publication, and the Chemical Biology Platform of the Broad Institute 
of Harvard and MIT for their assistance in this work.  The collection of tissue samples was 
supported by the Ted and Eileen Pasquarello Tissue Bank for Hematologic Malignancies.  We 
thank Roberto Bellucci for preparing and providing normal primary cells.  This work was 
supported by the Multiple Myeloma Research Foundation and the Brent Leahey Fund. 
 
 
Author contributions: 
 
EAN designed the research, performed experiments, and wrote the paper; SRW designed the 
research and performed experiments; AK, LBG, HI and TH performed experiments; DC and 
KCA designed the research; DAF designed the research and wrote the paper.  
 
The authors declare no financial conflicts of interest. 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From   23
References 
 
1.  Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer 
Lett. 2007;251:199-210. 
2.  Nelson EA, Walker SR, Alvarez JV, Frank DA. Isolation of unique STAT5 targets by 
chromatin immunoprecipitation-based gene identification. J Biol Chem. 2004;279:54724-54730. 
3.  Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a 
regulatory region frequently mutated in lymphomas. Oncogene. 2007;26:224-233. 
4.  Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of 
signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2005;2:315-
324. 
5.  Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 
signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-
115. 
6.  Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the 
bone microenvironment in the pathophysiology and therapeutic management of multiple 
myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 
2006;42:1564-1573. 
7.  Burger R, Guenther A, Bakker F, et al. Gp130 and ras mediated signaling in human 
plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J. 
2001;2:42-53. 
8.  Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic 
leukemia contain STAT1 and STAT3 constitutively phosphorylated on serine residues. J Clin 
Invest. 1997;100:3140-3148. 
9.  Lynch RA, Etchin J, Battle TE, Frank DA. A small-molecule enhancer of signal 
transducer and activator of transcription 1 transcriptional activity accentuates the 
antiproliferative effects of IFN-gamma in human cancer cells. Cancer Res. 2007;67:1254-1261. 
10.  Wagner BJ, Hayes TE, Hoban CJ, Cochran BH. The SIF binding element confers 
sis/PDGF inducibility onto the c-fos promoter. Embo J. 1990;9:4477-4484. 
11.  Nelson EA, Walker SR, Li W, Liu XS, Frank DA. Identification of human STAT5-
dependent gene regulatory elements based on interspecies homology. J Biol Chem. 
2006;281:26216-26224. 
12.  Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human 
myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. 
Blood. 1993;82:3712-3720. 
13.  Chou TC. Theoretical basis, experimental design, and computerized simulation of 
synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621-681. 
14.  Szczepek AJ, Belch AR, Pilarski LM. Expression of IL-6 and IL-6 receptors by 
circulating clonotypic B cells in multiple myeloma: potential for autocrine and paracrine 
networks. Exp Hematol. 2001;29:1076-1081. 
15.  Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol. 2000;37:1-11. 
16.  Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in 
multiple myeloma. Cell Cycle. 2004;3:1259-1262. 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From   24
17.  Pedranzini L, Dechow T, Berishaj M, et al. Pyridone 6, a pan-janus-activated kinase 
inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 2006;66:9714-9721. 
18.  Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. Combined 
disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce 
apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood. 
2004;104:3712-3721. 
19.  Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. 
Anticancer Drugs. 2002;13:1-13. 
20.  Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in 
clinical trials. Curr Pharm Des. 2004;10:2289-2298. 
21.  Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S. Requirement of serine 
phosphorylation for formation of STAT-promoter complexes. Science. 1995;267:1990-1994. 
22.  Bouree P, Chaput JC, Krainik F, Michel H, Trepo C. [Double-blind controlled study of 
the efficacy of nifuroxazide versus placebo in the treatment of acute diarrhea in adults]. 
Gastroenterol Clin Biol. 1989;13:469-472. 
23.  Tavares LC, Penna TC, Amaral AT. Synthesis and biological activity of nifuroxazide and 
analogs. Boll Chim Farm. 1997;136:244-249. 
24.  Masunari A, Tavares LC. A new class of nifuroxazide analogues: synthesis of 5-
nitrothiophene derivatives with antimicrobial activity against multidrug-resistant Staphylococcus 
aureus. Bioorg Med Chem. 2007;15:4229-4236. 
25.  Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr 
Opin Genet Dev. 2007;17:8-14. 
26.  Verma A, Kambhampati S, Parmar S, Platanias LC. Jak family of kinases in cancer. 
Cancer Metastasis Rev. 2003;22:423-434. 
27.  Stein MN, Flaherty KT. CCR drug updates: sorafenib and sunitinib in renal cell 
carcinoma. Clin Cancer Res. 2007;13:3765-3770. 
28.  Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. STAT3 is required for the 
oncogenic effects of non-small-cell lung cancer-associated mutations of the EGF receptor. 
Cancer Res. 2006;66:3162-3168. 
29.  Ni Z, Lou W, Leman ES, Gao AC. Inhibition of constitutively activated stat3 signaling 
pathway suppresses growth of prostate cancer cells. Cancer Res. 2000;60:1225-1228. 
30.  Jain N, Zhang T, Fong SL, Lim CP, Cao X. Repression of Stat3 activity by activation of 
mitogen-activated protein kinase (MAPK). Oncogene. 1998;17:3157-3167. 
31.  Richon VM, O'Brien JP. Histone deacetylase inhibitors: a new class of potential 
therapeutic agents for cancer treatment. Clin Cancer Res. 2002;8:662-664. 
32.  Aron JL, Parthun MR, Marcucci G, et al. Depsipeptide (FR901228) induces histone 
acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells 
concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP 
protein. Blood. 2003;102:652-658. 
 
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From   25
Figure Legends 
 
Figure 1.  Nifuroxazide inhibits STAT3-dependent gene expression. a. Chemical structure of 
nifuroxazide. b.  STAT3 and NF-κB reporter cells were pretreated with nifuroxazide at the 
indicated concentrations for 1 hour, after which cells were stimulated with IL-6 or TNF-α, 
respectively, for 6 hours.  Luciferase activity was quantitated by luminometry. 
 
Figure 2.  Nifuroxazide inhibits STAT3, Jak2, and Tyk2 tyrosine phosphorylation.  a.  
U266 cells were incubated with the indicated concentration of nifuroxazide for 24 hours, after 
which whole cell lysates were prepared, and Western blot analysis was performed using 
antibodies specific for tyrosine phosphorylated STAT3 (p-tyr STAT3) and total STAT3.  b.  
U266 cells were incubated for the indicated times with 10 μM nifuroxazide.  Western blots were 
performed for tyrosine phosphorylated STAT3, serine phosphorylated STAT3 (p-ser STAT3), 
and total STAT3.  c.  INA6 cells were incubated with 10 μM nifuroxazide or vehicle for 6 hours, 
after which immunoprecipitation was performed followed by Western blotting with the indicated 
antibodies.  Quantitation of bands is shown for each panel. 
 
Figure 3.  Nifuroxazide reduces the expression of Mcl-1.  a. U266 cells were treated with 10 
μM nifuroxazide for 24 hours, and Mcl-1 mRNA expression was quantitated by quantitative RT-
PCR, using HPRT as an invariant control.  b. U266 and INA6 cells were treated with 10 μM 
nifuroxazide for the indicated times, and Western blot analysis was performed using antibodies 
to Mcl-1 or β-actin, which served as a loading control.  Quantitation of the western blot is shown 
at right. 
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Figure 4.  Nifuroxazide inhibits the viability of MM cells containing constitutive STAT3 
phosphorylation.  a.  MM cells containing STAT3 phosphorylation (U266 and INA6), MM 
cells without STAT3 phosphorylation (RPMI 8226 and H929), and PBMCs from normal donors 
were treated with the indicated concentrations of nifuroxazide for 48 hours.  Cell viability was 
measured using an ATP-dependent bioluminescence assay.  b. Bone marrow aspirates from MM 
patient samples were treated with the indicated concentrations of nifuroxazide for 72 hours.  Cell 
viability was measured using an ATP-dependent bioluminescence assay.  c.  U266 cells cultured 
in the presence or absence of BMSC were treated with the indicated concentration of 
nifuroxazide for six hours, and then examined by Western analysis with the indicated antibodies.  
d. U266 cells were cultured in the presence or absence of BMSC for 48 hours with the indicated 
concentrations of nifuroxazide.  
3H thymidine incorporation was measured during the final 8 
hours of incubation to measure DNA synthesis. 
 
Figure 5.  The combination of nifuroxazide and depsipeptide results in enhanced 
cytotoxicity of MM cells.  a.  INA6 cells were incubated with the indicated doses of 
nifuroxazide and depsipeptide for 72 hours.  Viability was measured using an ATP-dependent 
bioluminescence assay.  b.  INA6 cells were incubated with the indicated doses of nifuroxazide 
and depsipeptide for 48 hours, after which Western analysis was performed with the indicated 
antibodies. 
 
Figure 6.  The combination of nifuroxazide and the MEK inhibitor UO126 results in 
enhanced cytotoxicity of MM cells and enhanced loss of STAT3 tyrosine phosphorylation.  
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a.  U266 cells were incubated with the indicated concentrations of nifuroxazide and UO126 for 
48 hours.  Viability was measured using an ATP-dependent bioluminescence assay.  b.  U266 
cells were incubated with the indicated concentrations of nifuroxazide and UO126 for 24 hours. 
Western blots were performed for tyrosine phosphorylated STAT3, serine phosphorylated 
STAT3 (p-ser STAT3), and total STAT3. 
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From   28
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From   29
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From   30
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From   31
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From   32
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From   33
 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 